Clinical Trials Browser

Phase 3 × niraparib × 1 year × Clear all

NCT05615818 2026-05-19

SAFIR-ABC10

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT04497844 2026-05-11

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT03748641 2026-05-08

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT06915025 2026-05-04

OVATION-3

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04475939 2026-05-01

ZEAL-1L

Phase 3 Completed

666 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03768063 2026-04-28

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT06388733 2026-04-01

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Phase 3 Recruiting

Brain Neoplasms, Glioblastoma

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 3 Active not recruiting

733 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT03602859 2025-12-31

FIRST

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03981796 2025-09-03

RUBY

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

NCT04915755 2025-07-16

ZEST

Phase 3 Active not recruiting

40 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms